AEON Biopharma Appoints CFO John Bencich with 25 Years Biotech Finance Expertise
AEON Biopharma has appointed John Bencich as Chief Financial Officer, bringing over 25 years of leadership in biotech finance and capital markets. Bencich’s track record of leading public‐company financings and driving clinical and regulatory milestones will support ABP-450’s accelerated entry through the FDA’s 351(k) biosimilar pathway.
1. Appointment Details
AEON Biopharma has named John Bencich as Chief Financial Officer to bolster its financial leadership as the company advances ABP-450 through critical regulatory milestones under the FDA’s 351(k) biosimilar pathway.
2. Executive Background
Bencich brings more than 25 years of experience in corporate strategy, capital market transactions and business development, most recently serving as Chief Executive Officer of Achieve Life Sciences and holding CFO roles at OncoGenex Pharmaceuticals, Integrated Diagnostics, Allozyne and Trubion Pharmaceuticals.
3. Strategic Impact
His proven ability to lead public‐company financings, strengthen intellectual property portfolios and drive regulatory progress is expected to deepen institutional engagement, streamline capital formation and position AEON for long‐term value creation as ABP-450 targets the $3 billion U.S. therapeutic neurotoxin market.